TAIHO PHARMA

We strive to
improve human
health and contribute
to a society enriched
by smiles

About Taiho

Becoming a truly global specialty pharma that meets the expectations of patients worldwide.

Our Business

Taiho Pharmaceutical creates innovative, highly valuable new drugs to support patients and the advancement of medicine, seeking to contribute to smiles and health for people all around the world.

News Releases

June 10, 2019

Taiho Pharmaceutical Forms Japan-based Corporate Venture Capital Firm to Foster Healthcare Startups in Japan
June 07, 2019

Otsuka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candidates in North America （PDF：111.1 KB）
March 11, 2019

Taiho Pharmaceutical Announces Personnel Changes（PDF：126.9 KB）
February 26, 2019

FDA Approves LONSURF^® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
February 05, 2019

Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor（PDF：82.0 KB）

Information

July 12, 2018

Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）